Management of small cell lung cancer

References

• Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. Natl Cancer Inst. 73(2), 383–389 (1984).
   Google Scholar
• Khuder SA. Effect of cigarette smoking on major histological types of lung cancer.Lung Cancer29\(Suppl. 2), 49 (2000).
   Google Scholar
• Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In: Cancer: Principles and Practice of Oncology DeVita VT, Jr. et al. (Eds.), 723–758 (1993).
   Google Scholar
• Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer28(3), 173–185 (2000).
   PubMed Web of Science ®Google Scholar
• •Review article of clinical and laboratory factors that are predictive of response and prognostic for survival in SCLC.
   Google Scholar
• Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research [Published erratum appears in BE J. Cancer 62(3), 550 (1990)1. Br. Cancer 61(4), 597–604 (1990).
   Google Scholar
• Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int. J. Cancer 39 (2), 146–149 (1987).
   Google Scholar
• Sambrook RJ, Girling DJ. A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. BE J. Cancer 84(11), 1447–1452 (2001). A British survey of clinicians' prescribing of chemotherapy in SCLC.
   Google Scholar
• Green R, Humphrey E, Close H, Panto M. Alkylating agents in bronchogenic carcinoma. Am.j Med. 46,516–525 (1969).
   PubMed Web of Science ®Google Scholar
• Bunn P, Cohen M, Ihde DC et al. Advances in small cell bronchogenic carcinoma. Cancer 7i-eat. Rep. 61,333-342 (1977).
   Google Scholar
• Aisner J. Extensive-disease small cell lung cancer: the thrill of victory;the agony of defeat. 1 Clin. Oncol 12,658–665 (1996).
   Google Scholar
• Pujol JL, Carestia L, Daures JR Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br. Cancer 83(1), 8–15 (2000).
   Google Scholar
• •Meta-analysis exploring the role of cisplatin in treatment of SCLC. Cisplatin-containing regimens found to be associated with higher response rates and survivals.
   Google Scholar
• Mascaux C, Paesmans M, Berghmans T et al A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer30(1), 23–36 (2000).
   PubMed Web of Science ®Google Scholar
• •Meta-analysis showing survival advantage to regimens containing etoposide alone or in combination with cisplatin.
   Google Scholar
• Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann. Oncol 5(7), 601–607 (1994).
   Google Scholar
• Lassen U, Kristjansen PE, Osterlind K et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann. Oncol 7(4), 365–371 (1996).
   Google Scholar
• Wolf M, Havemann K, Drings P et al Alternating chemotherapy with doxorubicin, ifosphamide and vincristine
   Google Scholar
• •• plus cisplatin, and etoposide versus doxorubicin, ifosphamide, and vincristine plus carboplatin, and etoposide in small cell lung cancer. In: Carboplatin (JMS): Current Perspectives and Future Directions. Bunn P et al (Eds.), 283–294 (1990).
   Google Scholar
• Krug LM, Grant SC, Miller VA, Ng KK, Kris MG. Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors and BEC2 plus BCG vaccination. Semin. Oncol 26(5 Suppl. 15), 55–61 (1999).
   Google Scholar
• Klasa RJ, Murray N, Coldman AJ. Dose- intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.j Clim Oncol 9(3), 499–508 (1991).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Lung Cancer Working Party. Randomised trial of four-drug vs. less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. BE J: Cancer 73 (3), 406–413 (1996).
   Google Scholar
• Arriagada R, Le Chevalier T, Pignon JP et al Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. Merl 329(25), 1848–1852 (1993).
   Google Scholar
• Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 348,563–566 (1996).
   PubMedGoogle Scholar
• •MRC trial showing higher toxicity and inferior survival of oral etoposide when compared to combination iv. chemotherapy.
   Google Scholar
• Souhami RL, Spiro SG, Rudd RM et al. Five- day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. Natl Cancer Inst. 89(8), 577–580 (1997).
   Google Scholar
• •London Lung Cancer Group study demonstrating inferiority of oral etoposide to CAV/PE in terms of survival and quality of life and supporting findings of MRC
   Google Scholar
• Murray N, Livingston R, Shepherd F et al. Randomized study of CODE versus alternating CAV/PE for extensive-stage small cell lung cancer: An Intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J: Clin. Oncol 17(8), 2300–2308 (1999).
   Google Scholar
• Souhami RL, Rudd R, Ruiz de Elvira MC et al. Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial. Clin. Oncol 12(9), 1806–1813 (1994).
   Google Scholar
• Sculier JP, Paesmans M, Bureau G et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a Phase III randomized study conducted by the European Lung Cancer Working Party. J: Clin. Oncol 11(10), 1858–1865 (1993).
   Google Scholar
• Masutani M, Ochi Y, Kadota A etal. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncology Reports 7(2), 305–310 (2000).
   Google Scholar
• Woll PJ, Hodgetts J, Lomax L et al. Can cytotoxic dose-intensity be increased by using granulocyte colony- stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J: Clin. Oncol 13(3), 652–659 (1995).
   Google Scholar
• Pujol JL, Douillard JY, Riviere A et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized Phase III study. Clin. Oncol 15(5), 2082–2089 (1997).
   Google Scholar
• Steward WP, von Pawel J, Gatzemeier U et al Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. j Clin. Oncol 16(2), 642–650 (1998).
   Google Scholar
• Thatcher N, Girling DJ, Hopwood P et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.j Clin. Oncol 18(2), 395–404 (2000).
   Google Scholar
• ••Recent MRC randomized trial showing animproved survival from use of dose-intense chemotherapy supported by G-CSE
   Google Scholar
• Elias A. Dose-intensive therapy in small cell lung cancer. Chest113 (1 Suppl.), 101S-106S (1998).
   Google Scholar
• Humblet Y, Symann M, Bosly A et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J: Clin. Oncol 5(12), 1864–1873 (1987).
   Google Scholar
• Woll P, Thatcher N, Lomax L et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized Phase II trial in small-cell lung cancer patients. j Clin. Oncol 19(3), 712–719 (2001).
   Google Scholar
• Leyvraz S, Perey L, Rosti G et al. Multiple courses of high-dose ifosfamide, carboplatin and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J: Clin. Oncol 17(11), 3531–3539 (1999).
   Google Scholar
• Elias A, Ibrahim J, Skarin AT et al. Dose- intensive therapy for limited-stage small-cell lung cancer: long- term outcome. J: Clin. Oncol 17(4), 1175 (1999).
   Google Scholar
• Giaccone G, Dalesio 0, McVie GJ et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J: Clin. Oncol 11(7), 1230–1240 (1993).
   Google Scholar
• •Lack of benefit to 12 cycles of combination chemotherapy when compared to six cycles.
   Google Scholar
• Spiro SG, Souhami RL, Geddes DM et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br. Cancer 59 (4), 578–583 (1989) .
   Google Scholar
• Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (sac). II, Quality of life. Medical Research Council Lung Cancer Working Party. Br. Cancer68(6), 1157–1166 (1993).
   Google Scholar
• Sculier JP, Berghmans T, Castaigne C et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 19 (2), 141–151 (1998).
   PubMedGoogle Scholar
• Einhorn LH, Crawford J, Birch R et al. Cisplatin plus etoposide consolidation
   Google Scholar
• •• following cyclophosphamide, doxorubicin and vincristine in limited small-cell lung cancer. 1 Clin. Oncol 6(3), 451–456 (1988).
   Google Scholar
• Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J. Cancer 32A(3), 438–443 (1996).
   Google Scholar
• Sculier JP, Paesmans M, Bureau G et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. Clin. Oncol 14(8), 2337–2344 (1996).
   Google Scholar
• Broder LE, Sridhar KS, Selawry OS et al A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine and etoposide (VAPE) with cyclophosphamide, CCNU and methotrexate (C CM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification. Am. J. Clin. Oncol 17(6), 527–537 (1994).
   Google Scholar
• Huisman C, Postmus PE, Giaccone G, Smit EF. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer 7i-eat. Rev 25(4), 199–206 (1999).
   Google Scholar
• Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC. Cydophosphamide, doxorubicin and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer 7irat. Rep. 71(10), 941–944 (1987).
   Google Scholar
• •Trial justifying the use of CAV as salvage after failure of PE.
   Google Scholar
• Sculier JP, Klastersky J, Libert P et al. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer [LETTER]. Eur Cancer26(8), 919–921 (1990).
   PubMedGoogle Scholar
• von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol 17(2), 658–667 (1999).
   Google Scholar
• •Comparison of CAV and topotecan in recurrent SCLC showing equivalent efficacy but greater control of certain symptoms by topotecan.
   Google Scholar
• Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl. I Med. 327(23), 1618–1624 (1992).
   Google Scholar
• Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited- stage small-cell carcinoma of the lung? A meta-analysis. Clin. °rico]. 10(6), 890–895 (1992).
   PubMed Web of Science ®Google Scholar
• Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group data base. J. Clin. Oncol 8(9), 1563–1574 (1990).
   Google Scholar
• Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 99(6), 1425–1432 (1991).
   Google Scholar
• Jacoulet P, Depierre A, Moro D et al Long- term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Francaise. Ann. Oncol 8(10), 1009–1014 (1997).
   Google Scholar
• Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol 11(2), 336–344 (1993).
   Google Scholar
• Goto K, Nishiwalki Y, Takada M et al. Final results of a Phase HI study of concurrent velsus sequential thoracic radiotherapy (TR'T) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) study. Proc. Am Soc. Clin. °rico'. Atlanta, USA, 468a (1999).
   Google Scholar
• Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. Clin. °rico]. 15(9), 3030–3037 (1997).
   Google Scholar
• Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl. I Med. 316(15), 912–918 (1987).
   Google Scholar
• Perry MC, Herndon JE, 3rd, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.1 Clin. 0=1 16(7), 2466–2467 (1998).
   Google Scholar
• Humblet Y, Bosquee L, Weynants P, Symann M. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. Bone Manvw Transplant. 18\(Suppl. 1), S36-39 (1996).
   Google Scholar
• van de Velde H, Bosquee L, Weynants P et al. Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Universite Catholique de Louvain, Brussels and Liege, Belgium. Ann. awl 10(9), 1051–1057 (1999).
   Google Scholar
• De Ruysscher D, Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother. Oncol 55(1), 1–9 (2000).
   PubMedGoogle Scholar
• Turrisi AT, 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl. I Med. 340(4), 265–271 (1999).
   Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial venusdelayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. Clin. Oncol 15(3), 893–900 (1997).
   Google Scholar
• Bonner JA, Sloan JA, Shanahan TG et al. Phase III comparison of twice-daily split-course irradiation versusonce-daily irradiation for patients with limited stage small-cell lung carcinoma. I Clin. Oncol 17(9), 2681–2691 (1999).
   Google Scholar
• Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl. Med. 341(7), 476–484 (1999).
   Google Scholar
• ••Meta-analysis of PCI trials in SCLC.
   Google Scholar
• Arriagada R, Le Chevalier T, Bone F et al Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Natl Cancer Inst. 87(3), 183–190 (1995).
   Google Scholar
• Gregor A, Cull A, Stephens RJ et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur. j Cancer 33(11), 1752–1758 (1997).
   Google Scholar
• •Randomized trial confirming benefits of PCI in improving survival and reducing risk of brain metastases without significant effect on cognitive functioning.
   Google Scholar
• Komaki R, Meyers CA, Shin DM et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int. J. Rachat. Oncol Biol. Phys. 33(1), 179–182 (1995).
   Google Scholar
• Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 2(7820), 63–65 (1973).
   PubMed Web of Science ®Google Scholar
• Hage R, Elbers JR, Brutel de la Riviere A, van den Bosch JM. Surgery for combined type small cell lung carcinoma. Thorax 53(6), 450–453 (1998).
   PubMedGoogle Scholar
• Lassen U, Hansen IIf I. Surgery in limited stage small cell lung cancer. Cancer Treat. Rev 25(2), 67–72 (1999).
   Google Scholar
• •Review article examining role of surgery in early-stage SCLC.
   Google Scholar
• Davis S, Wright PW, Schulman SF et al Long-term survival in small-cell carcinoma of the lung: a population experience. J. Clin. Oncol 3(1), 80–91 (1985).
   Google Scholar
• Shields TVV, Higgins GA, Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J. Thorac. Carcliovasc. Surg. 84(4), 481–488 (1982).
   Google Scholar
• Shah SS, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment of small cell lung cancer. Ann. Thorac. Surg. 54(3), 498–501 (1992).
   Google Scholar
• Coolen L, Van den Eeckhout A, Deneffe G, Demedts M, Vansteenkiste J. Surgical treatment of small cell lung cancer. Eur. Camliothorac. Surg. 9(2), 59–64 (1995).
   Google Scholar
• Martini N, Wittes RE, Hilaris BS et al. Oat cell carcinoma of the lung. Clin. Bull. 5 (4), 144–148 (1975).
   Google Scholar
• Johnson DH, Einhorn LH, Mandelbaum I, Williams SD, Greco FA. Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. Chest 92 (2), 241–246 (1987).
   PubMedGoogle Scholar
• Shepherd FA, Ginsberg RJ, Evans WK et al. Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. j Thorac. Camliovasc. Surg. 86(4), 498–506 (1983).
   Google Scholar
• Meyer JA. Five-year survival in treated stage I and II small cell carcinoma of the lung. Ann. Thorac. Surg. 42(6), 668–669 (1986).
   Google Scholar
• Karrer K. Rationale for surgery as the first step in the multimodality treatment of small cell lung cancer (SCLC). Chemother. 1(3), 147–150 (1989).
   Google Scholar
• Salzer GM, Muller LC, Huber H et al. Operation for N2 small cell lung carcinoma. Ann. Thorac. Sing 49(5), 759–762 (1990).
   Google Scholar
• Meyer JA, Gullo JJ, Ikins PM et al. Adverse prognostic effect of N2 disease in treated small cell carcinoma of the lung. J. Thorac. Camliovasc. Surg. 88(4), 495–501 (1984).
   Google Scholar
• Shepherd FA, Evans WK, Feld R et al Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung.j Clin. Oncol 6(5), 832–838 (1988).
   Google Scholar
• Osterlind K, Hansen M, Hansen IIf I, Dombemowsky P. Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. Eur. Cancer Clin. Oncol 22(5), 589–593 (1986).
   Google Scholar
• Shepherd FA, Ginsberg R, Patterson GA et al Is there ever a role for salvage operations in limited small-cell lung cancer? J. Thorac. Camliovasc. Surg. 101(2), 196–200 (1991).
   Google Scholar
• Lad T, Piantadosi S, Thomas P et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106(6 Suppl.), 320S-323S (1994).
   Google Scholar
• Fujimori K, Yokoyama A, Kurita Y, Terashima M. A pilot Phase II study of surgical treatment after induction chemotherapy for resectable stage Ito IIIA small cell lung cancer. Chest111(4), 1089–1093 (1997).
   PubMedGoogle Scholar
• Eberhardt W, Stamatis G, Stuschke M et al. Aggressive trimodality treatment including chemoradiation induction and surgery (s) in LD-small-cell lung cancer a_D-saq (stages I-ITN-long-term results. Proc. Am. Soc. Clin. Oncol Los Angeles, USA, 450a (1998).
   Google Scholar
• Noda K, Nishiwaki Y, Kawahara M et al Randomized Phase III study of irinotecan (CPT-I1) and cisplatin versusetoposide and cisplatin in extensive- disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511). Proc. Am. Soc. Clin. Om& New Orleans, USA, 483a (2000).
   Google Scholar
• •Japanese study suggesting superiority of irinotecanicisplatin combination to PE. This has led to a number of further trials.
   Google Scholar
• Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small- cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol 13(6), 1430–1435 (1995).
   Google Scholar
• Smit EF, Fokkema E, Biesma B et al. A Phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. BE J. Cancer 77(2), 347–351 (1998).
   Google Scholar
• Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. A Phase I study of paclitaxel, etoposide and cisplatin in extensive stage small cell lung cancer. Clin. Cancer Res, 5(11), 3419–3424 (1999).
   Google Scholar
• Glisson BS, Kurie JM, Perez-Soler R et al. Cisplatin, etoposide and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J. Clin. Oncoll7 (8), 2309–2315 (1999).
   Google Scholar
• Mavroudis M, Papadakis E, Veslemes M et al A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as front-line treatment in patients with small cell lung cancer (SCLC). Ann. Oncol. 12(4), 463–470 (2001).
   PubMedGoogle Scholar
• Groen HJ, Fokkema E, Biesma B et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: a non-cross-resistant schedule. J. Clin. Oncol 17 (3), 927–932 (1999).
   Google Scholar
• Cormier Y, Eisenhauer E, Muldal A etal. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol 5(3), 283–285 (1994).
   Google Scholar
• Van der Lee I, Postmus P, Smit E et al. The activity of gemcitabine in patients with resistant small cell lung cancer (SCLC): a Phase II study. Proc. Am. Soc. Clin. Om& Atlanta, USA, 476a (1999).
   Google Scholar
• Carmichael J, Allerheiligen S, Walling J. A Phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Sernin. Oncol 23(5 Suppl. 10), 55–59 (1996).
   Google Scholar
• Ruotsalainen TM, Halme M, Tamminen K etal. Concomitant chemotherapy and IFN-a for small cell lung cancer: a randomized multicenter Phase III study. .1. Interferon Cytokine Res. 19 (3), 253–259 (1999).
   Google Scholar
• Mattson K, Niiranen A, Pyrhonen S et al Natural interferon-a as maintenance therapy for small cell lung cancer. Eur. Cancer 1387–1391 (1992).
   Google Scholar
• Mattson K, Niiranen A, Ruotsalainen T et al Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. j Interferon Cytokine Res. 17(2), 103–105 (1997).
   Google Scholar
• Kelly K, Crowley JJ, Bunn PA et al. Role of recombinant interferon-a-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. Clin. Oncol 13(12), 2924–2930 (1995).
   Google Scholar
• Ruotsalainen T, Halme M, Isokangas OP et al Interferon-a and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer — a feasibility study. Anticancer Drugs 11 (2), 101–108 (2000).
   Google Scholar
• Jett JR, Maksymiuk AVV, Su JQ et al. Phase fa trial of recombinant interferon-yin complete responders with small-cell lung cancer. j Glitz 0=1 12(11), 2321–2326 (1994).
   Google Scholar
• van Zandwijk N, Groen HJ, Postmus PE et al Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised Phase III study of the EORTC Lung Cancer Cooperative Group. Eur j Cancer 33(11), 1759–1766 (1997).
   PubMed Web of Science ®Google Scholar
• Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Cum Opin. Oncol 12(6), 564–573 (2000).
   Google Scholar
• Yip D, Ahmad A, Karapetis CS, Hawkins CA, Harper PG. Matrix metalloproteinase inhibitors: applications in oncology. Invest. New Drugs 17(4), 387–399 (1999).
   Google Scholar
• Shepherd F, Giaccone G, Debruyne C, Hirsh V, Smylie H. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study. Proc. Am. Soc. Clin. Oncol San Francisco, USA, 4a (2001).
   Google Scholar
• Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. 5(6), 1319–1323 (1999).
   Google Scholar
• Druker B, Talpaz M, Resta D eta]. Effficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl I Merl 344, 1031–1037 (2001).
   Google Scholar
• Strickland L, Letson G, Muro-Cacho C. Gastrointestinal stromal tumors. Cancer Control8(3), 252–261 (2001).
   PubMedGoogle Scholar
• Krystal GVV, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI-571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6(8), 3319–3326 (2000). iii Bondzi C, Litz J, Dent P, Krystal GW. Sit family kinase activity is required for Kit-mediated mitogen- activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth Differ 11(6), 305–314 (2000).
   Google Scholar
• Parkin DM, Sankaranarayanan R. Overview on small cell lung cancer in the world: industrialized countries, Third World, Eastern Europe. Anticancer Res. 14(1B), 277–282 (1994).
   Google Scholar
• Cinciripini PM, Hecht SS, Henningfield JE, Manley MW Kramer BS. Tobacco addiction: implications for treatment and cancer prevention. j Natl Cancer Inst. 89(24), 1852–1867 (1997).
   PubMedGoogle Scholar
• Chute JP, Venzon DJ, Hankins L etal. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin. Proc. 72(10), 901–912 (1997).
   Google Scholar
• Lassen UN, Hirsch FR, Osterlind K, Bergman B, Dombernowsky P Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung- Cancer 20 (3), 151–160 (1998).
   Google Scholar
• Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. j Clin. Oncol 17(6), 1794–1801 (1999). Analysis of ED SCLC patients enrolled in Phase III trials in North America and in the SEER database show a very modest improvement in survival over the period 1972–1990.
   Google Scholar